Retrogenix advances medical research and speeds up drug discovery for its clients by providing a unique service which identifies specific cell surface and secreted protein interactions in human cells. Retrogenix now has research agreements with nineteen of the top twenty global pharmaceutical companies, numerous drug discovery companies and many leading academic and non-for-profit institutions around the world.

Our results have been published in high-impact journals including Nature, Molecular Cancer, Cancer Cell, mBio and Oncotarget and members of our team are regularly invited to present at international conferences. In 2015, Retrogenix won its first Queen’s Award for Enterprise – the UK’s most prestigious business accolade – in recognition of its innovative work in developing and commercialising the cell microarray technology. This was followed in 2017 by a second Queen’s Award for outstanding achievements in international trade.

As well as the unique cell microarray technology, Retrogenix also holds one of the world’s largest collections of plasma membrane and secreted protein clones which are individually expressed in human cells. The collection now exceeds 5,900 full-length expression clones, with many proteins represented by multiple variants.

Retrogenix is headquartered in the High Peak, UK, and all project work is undertaken by highly skilled scientists in our specialist laboratory facilities on-site. The company also has a US office in Cambridge, MA. Retrogenix continues to build on its global reputation and the team is rapidly expanding to keep pace with the growing demand for its services.

Our History

In 2008, pharmaceutical scientist Dr Jim Freeth identified a powerful, physiologically-based approach for target deconvolution and receptor identification using human cells. Realising that this approach could overcome a major hurdle in medical research and drug discovery, Jim formed Retrogenix Limited with fellow scientist Jo Soden to develop the cell microarray technology. The team successfully raised private equity investment in 2009 and launched the cell microarray screening service in 2010.

Quickly out-growing its start-up labs in Sheffield, UK, Retrogenix relocated to bespoke laboratory facilities at Whaley Bridge in the UK’s Peak District National Park in 2012, expanding the team to deliver the increasing amount of project work and to continue with the essential research and development that ensures the cell microarray technology delivers exceptional results.

By 2013, the Retrogenix technology had facilitated a major breakthrough for a group studying a particularly deadly form of malaria which kills around half a million children per year. This advance paves the way for vaccines and therapies to be developed. The results of this study were published in the leading scientific journal Nature (2013; 498:502) – this was quickly followed by other studies showcasing the success of the technology in a variety of different research projects. Late in 2018 Retrogenix moved again to larger purpose built facilities in the Peak District in order serve increasing demand for its services worldwide, and continue its rapid growth.

A current double Queen’s Award holder, Retrogenix continues to lead the way in receptor identification and off-target profiling and recently extended its reach into new research areas including specificity screening for CAR-T cells and immune checkpoint pairing.

The University of Sheffield
Aveo Oncology - The Human Response
Theraclone Sciences
Bluebird Bio
The Center for Infectious Disease Research
Compugen Logo
The University of Copenhagen
Lund University
NIH - National Institutes of Health
The University of Pennsylvania
Scripps Florida - The Scripps Research Institute
Peptinnovate Ltd - Unlocking Nature's Potential
Capella Bioscience Logo
Sanofi Logo
Unum Theraputics Logo
Celyad Logo
…there was "no doubt" that the breakthrough in identifying EPCR was due to the Retrogenix screening tool.
Assistant Professor Thomas Lavstsen, University of Copenhagen. Quoted in BioWorld Today, June 2013